Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc.
1:17-cv-00389
Overview
Parties
Defendant
Mylan Pharmaceuticals Inc. Operating Company
Represented By
8 Attorneys ListedDevlin Law Firm
1526 Gilpin Avenue, 19806
Young, Conaway, Stargatt & Taylor LLP
Rodney Square, 1000 North King Street
Plaintiff
Novartis AG Operating Company
Represented By
7 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Novartis Pharmaceuticals Corporation Operating Company
Represented By
7 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 5 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | Asserted | Asserted Patent | View Official Patent → |
| 🇬🇧 United Kingdom | United Kingdom Counterpart | View Official Patent → | |
| 🇬🇧 United Kingdom | United Kingdom Counterpart | View Official Patent → | |
| 🌐 PCT International (WIPO) | PCT World Application | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → |
Breckenridge Pharmaceutical, Inc. v. Novartis AG
Roxane Laboratories, Inc. et al. v. Novartis AG
Par Pharmaceutical, Inc. et al. v. Novartis AG
BRECKENRIDGE PHARMACEUTICAL, INC. v. Novartis AG
Par Pharmaceutical, Inc. et al. v. Novartis AG
Par Pharmaceutical, Inc. et al. v. Novartis AG
Novartis Pharmaceuticals Corporation v. Breckenridge Pharmaceutical Inc.
Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc.
Novartis Pharmaceuticals Corporation v. Breckenridge Pharmaceutical Inc.
Patents Involved
There are 4 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US5665772
O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
|
Filed: 1993-09-24
Issued: 1997-09-09
|
Expired (Term Ended)
+2176d PTA
Expires: 2019-09-09
|
|
|
US8778962
Treatment of solid tumors with rapamycin derivatives
|
Filed: 2012-07-11
Issued: 2014-07-15
|
Active (5.6 yrs remaining)
Expires: 2032-07-11
|
|
|
US8617598
Pharmaceutical compositions comprising colloidal silicon dioxide
|
Filed: 2012-06-05
Issued: 2013-12-31
|
Active (5.5 yrs remaining)
Expires: 2032-06-05
|
|
|
US7297703
Macrolides
|
Filed: 2004-12-23
Issued: 2007-11-20
|
Expired (Term Ended)
Expires: 2024-12-23
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, injunctive relief is barred.
High PTA (+2176 days) / In re Cellect scrutiny applies.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
20
Dispositive
0
Granted
0
Denied
0
Pending / Review
20
Motions by Category
Key Dispositive Motions & Rulings